Table 1.

Baseline demographics, diseases, treatments, side effects, blood values and infection parameters of 20 patients in reviewed case reports (y = years, ICI = Immune Checkpoint Inhibitor, irAE = Immune-related side effects, n.a. = not applicable)

Patient	Age (y)	Cancer disease	ICI	irAE (besides neutropenia)	Neutrophil count (G/l)	Hemoglobin values (g/l)	Thrombocyte count (G/l)	Reported strain	Fever	Antibiotic therapy
1	42	Melanoma	Ipilimumab	Rush	0.3	108	202	None	Yes	Yes
2	74	Melanoma	Ipilimumab	Not documented	0	62	158	None	Yes	Yes
3	77	Melanoma	Ipilimumab	Endocrine	0	88	71	R. plantocola and E. cloacae	Yes	Yes
4	49	Melanoma	Ipilimumab	None	0	Normal	Normal	None	Yes	Yes
5	70	Melanoma	Ipilimumab	Rush	0.3	70	n.a.	None	No	n.a.
6	35	Melanoma	Ipilimumab	None	0	76	256	None	Yes	Yes
3	54	Melanoma	Ipilimumab	Rush, endocrine	0	n.a.	127	None	Yes	Yes
8	74	Lung cancer (adenocarcinoma)	Nivolumab	Rush, hepatitis	0	n.a.	n.a.	S. aureus	No	Yes
9	48	Melanoma	Nivolumab and ipilimumab	None	0	115	< 5	None	Yes	Yes
10	38	Primary mediastinal B-cell lymphoma	Nivolumab	None	0	n.a.	n.a.	None	n.a.	n.a.
11	73	Lung cancer (adenocarcinoma)	Nivolumab	Colitis	0	n.a.	n.a.	None	Yes	Yes
12	74	Lung cancer (adenocarcinoma)	Nivolumab	None	0	119	249	None	n.a.	n.a.
13	57	Glioblastom	Nivolumab	Rush	0	68	5	Moxarella catarrhalis	Yes	Yes
14	51	Melanoma	Nivolumab and ipilimumab	Endocrine	0	77	346	None	n.a.	n.a.
15	56	Lunge cancer (adenocarcoma)	Nivolumab	None	0.1	100	40	Fusarium solani	Yes	Yes
16	59	Melanoma	Nivolumab and ipilimumab	Rush, hepatitis, colitis	0.3	n.a.	n.a.	None	n.a.	n.a.
17	73	Lung cancer (adenocarcinoma)	Pembrolizumab	Not documented	0	n.a.	n.a.	None	Yes	Yes
18	82	Lung cancer (pleomorphic carcinoma)	Pembrolizumab	Pneumonitis	0.1	Normal	Normal	None	Yes	Yes
19	65	Melanoma	Nivolumab and ipilimumab	Colitis	0	103	227	None	Yes	Yes
20	56	Melanoma	Nivolumab and anti-LAG-3	None	0	144	288	None	Yes	Yes